Article Figures & Data
Figures
- Fig. 1.
Schematic representation of the experimental protocols used in this study. Arrows represent individual intracortical applications of anti-NGF, anti-IgG, or vehicle injections. Each box represents a particular relevant manipulation: mic, microdialysis procedure;FG, intracortical fluorogold injections; CTA Ac1, first CTA acquisition trial; Test1, first CTA retention test; CTA Ac2, second CTA acquisition trial; Test2, second CTA retention test; IA ac, IA acquisition trial; IA test, IA retention test.
- Fig. 2.
Effects of 56 mm KCl (black bar) added to the perfusion medium on mean values (±SEM) of extracellular ACh release during the microdialysis procedure. **p < 0.01 compared against intact control. Note the lack of ACh release in the anti-NGF-treated hemispheres. The rest of the groups showed normal release of ACh after KCl stimulation.
- Fig. 3.
Schematic representation of repeated injections of anti-NGF mAbs into the IC, whereas the contralateral cortex received the corresponding vehicle treatment. Photomicrography of a coronal section showing the weak reaction for the AchE histochemistry in the anti-NGF-treated area (left) compared with the control side (right).
- Fig. 4.
Photomicrographs showing FG labeling of NBM cells projecting to the IC after either intracortical vehicle injections (top left) or anti-NGF injections (top right). Labeling of posteroventromedial thalamus (VPM) cells projecting to the IC of the same brain: thalamic cells ipsilateral to the vehicle-treated cortex (bottom left) and cell labeling in the thalamus ipsilateral to the anti-NGF-treated cortex (bottom right). The four photomicrographs were obtained from the same brain. Scale bar, 100 μm.
- Fig. 5.
Quantitative FG retrograde tracing of thalamic cells projecting to the IC (A) and forebrain cells projecting to the IC (B) in the anti-NGF-treated side and the contralateral vehicle-treated side. Int, Intact control; Veh, vehicle; A-Ig, anti-IgG;A-NG, anti-NGF. Comparisons were made against the intact control group. **p < 0.01.
- Fig. 6.
Effects of repeated anti-NGF or vehicle injections on CTA learning test. Aversion index expressed as mean (±SEM) percentage of baseline consumption during the test trial.A, Retention of a previously acquired conditioning.B, Test of a post-treatment CTA acquisition.Int, Intact control; Veh, vehicle;A-NG, anti-NGF. **p < 0.05 versus intact control.
- Fig. 7.
Effect of repeated anti-NGF or vehicle injections on IA learning test. A, Median (±IQ range) latency to enter the dark compartment. B, Total time spent in the safe compartment during the 600 sec test period. Int, Intact control; Veh, vehicle; A-NG, anti-NGF. **p < 0.01 versus intact control.
